Evaluation of the atrophogenic potential of different glucocorticoids using optical coherence tomography, 20-MHz ultrasound and profilometry; a double-blind, placebo-controlled trial

Cossmann, M; Welzel, Julia

doi:10.1111/j.1365-2133.2006.07369.x

Cited by 51 publications

(42 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Coßmann and Welzel investigated the atrophogenic potential of different glucocorticoids applied once daily to the volar part of both arms of healthy volunteers over a period of 4 weeks using OCT. The degree of epidermal thinning reflected the different potency of the treatments: clobetasol propionate induced the highest degree of atrophy, followed by betamethasone valerate and methylprednisolone aceponate (23).…”

Section: Discussionmentioning

confidence: 99%

“…In contrast, optical coherence tomography (OCT) as a non-invasive high-resolution method enables the evaluation of epidermal thickness and was shown to be useful for the early detection and monitoring of side effects such as thinning of the epidermis (20)(21)(22)(23)(24). Skin atrophy is usually determined on the volar forearm of healthy volunteers, whereas in the clinical setting, topical corticosteroids are usually applied to diseased skin and to sensitive skin areas such as the face and neck.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of the atrophogenic potential of hydrocortisone 1% cream and pimecrolimus 1% cream in uninvolved forehead skin of patients with atopic dermatitis using optical coherence tomography

Aschoff

Schmitt

Knuschke

et al. 2011

Experimental Dermatology

View full text Add to dashboard Cite

Topical corticosteroids are widely used to treat atopic dermatitis (AD), but their anti-inflammatory mode of action can be accompanied by several unwanted side effects including skin atrophy and telangiectasia. In this 8-week, investigator-blinded, intraindividual right-left comparison study with patients with mild-to-moderate AD, hydrocortisone 1% cream (HCT) was applied twice daily for 4 weeks on one side of forehead skin without clinical signs of AD and pimecrolimus 1% cream (PIM) on the other. Epidermal and dermal thickness were assessed by optical coherence tomography (OCT) and high-frequency ultrasound, respectively. Skin atrophy and telangiectasia were assessed by contact dermatoscopic photography (Dermaphot Ò ). Treatment with HCT leads to a significant decrease in epidermal thickness after only 2 weeks of treatment, while the decrease in PIM-treated sites was less pronounced and was not statistically significant. By 4 weeks after the end of treatment, epidermal thickness returned to baseline values. No dermal thinning or development of telangiectasia could be observed by means of ultrasound or Dermaphot Ò , respectively. In summary, this study indicates that a 2-week single course of topical treatment with a mildly potent steroid can cause transient epidermal thinning, an effect not seen in the PIM group. The slight decrease with PIMalthough not significant -could be due to normalization of the increased skin thickness caused by a subclinical inflammation in AD. This study suggests that PIM may be safer for treatment of AD in sensitive skin areas like the face, especially when repeated application is required.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Evaluation of the atrophogenic potential of hydrocortisone 1% cream and pimecrolimus 1% cream in uninvolved forehead skin of patients with atopic dermatitis using optical coherence tomography

Aschoff

Schmitt

Knuschke

et al. 2011

Experimental Dermatology

View full text Add to dashboard Cite

show abstract

“…This method has previously been used in similar type studies (11)(12)(13). For obtaining skin data on the forearm, the distance between epicondylos medialis humerii and processus styleoideus radii was measured.…”

Section: Subjects and Designmentioning

confidence: 99%

Skin Thickness in Children Treated With Daily or Periodical Inhaled Budesonide for Mild Persistent Asthma. The Helsinki Early Intervention Childhood Asthma Study

et al. 2010

View full text Add to dashboard Cite

ABSTRACT:In adults, asthma treatment with high doses of inhaled corticosteroids has resulted in dermal thinning. The aim of this study was to investigate the skin thickness in children with asthma during budesonide treatment. In a double-blind study, 113 children, 5-10 y old, with persistent asthma received budesonide 400 g twice daily for 1 mo and thereafter 200 g twice daily for 5 mo. Thereafter, 56 children received 100 g twice daily for 1 y, whereas 57 other children used budesonide periodically for exacerbations. An additional 54 children were treated with disodium cromoglycate (DSCG) for 18 mo. Skin thickness was measured on each forearm before and after treatment for 6, 12, and 18 mo using a 20-MHz high-resolution ultrasonic device. The initial 6-mo budesonide treatment resulted in a greater reduction in mean skin thickness in the forearms compared with DSCG (right: Ϫ35.9 versus Ϫ5.9 m; p ϭ 0.004; left: Ϫ30.6 versus Ϫ7.3 m; p ϭ 0.03). At month 18, the inter-group differences were no longer significant. Budesonide inhalations in daily doses of 400 -800 g in prepubertal children with newly detected asthma may cause minor dermal thinning. The changes were reversible during low dose or periodic treatment with budesonide. (Pediatr Res 67: 221-225, 2010)

show abstract

“…in the diagnostics of nonmelanoma skin cancer, for the measurement of tumor thickness of melanocytic lesions, for the evaluation of epidermal changes after different topical treatments and in the assessment of psoriatic nail disorders [13,15,16,17,18,19]. …”

Section: Introductionmentioning

confidence: 99%

High-Definition Optical Coherence Tomography for the in vivo Detection of Demodex Mites

et al. 2012

View full text Add to dashboard Cite

Background: Demodex mites are involved in different skin diseases and are commonly detected by skin scrape tests or superficial biopsies. A new high-definition optical coherence tomography (HD-OCT) with high lateral and axial resolution in a horizontal (en-face) and vertical (slice) imaging mode might offer the possibility of noninvasive and fast in vivo examination of demodex mites. Methods: Twenty patients with demodex-related skin diseases and 20 age- and gender-matched healthy controls were examined by HD-OCT. Mites per follicle and follicles per field of view were counted and compared to skin scrape tests. Results: HD-OCT images depicted mites in the en-face mode as bright round dots in groups of 3–5 mites per hair follicle. In the patients with demodex-related disease, a mean number of 3.4 mites per follicle were detected with a mean number of 2.9 infested follicles per area of view compared to a mean of 0.6 mites in 0.4 infested follicles in the controls. The skin scrape tests were negative in 21% of the patients. Conclusion: The innovative HD-OCT enables fast and noninvasive in vivo recognition of demodex mites and might become a useful tool in the diagnosis and treatment monitoring of demodex-related skin diseases.

show abstract

Evaluation of the atrophogenic potential of different glucocorticoids using optical coherence tomography, 20-MHz ultrasound and profilometry; a double-blind, placebo-controlled trial

Cited by 51 publications

References 30 publications

Evaluation of the atrophogenic potential of hydrocortisone 1% cream and pimecrolimus 1% cream in uninvolved forehead skin of patients with atopic dermatitis using optical coherence tomography

Evaluation of the atrophogenic potential of hydrocortisone 1% cream and pimecrolimus 1% cream in uninvolved forehead skin of patients with atopic dermatitis using optical coherence tomography

Skin Thickness in Children Treated With Daily or Periodical Inhaled Budesonide for Mild Persistent Asthma. The Helsinki Early Intervention Childhood Asthma Study

High-Definition Optical Coherence Tomography for the in vivo Detection of Demodex Mites

Contact Info

Product

Resources

About